The results from this study of 125 patients with metastatic prostate cancer after 4 years of follow-up show that patients receiving PROSTVAC™ had a statistically significantly longer median overall survival by 8.5 months (p=0.015) compared to the control group. Currently the only approved treatment for advanced prostate cancer extends median overall survival by an average of approximately 2 months. In addition, PROSTVAC™ also had a favourable safety and tolerability profile.
This is not necessarily true - the results for Provenge are for 3-year survival. We do not currently know what the 4-year survival rate is. If the remaining Provenge patients are still alive at 4 years then the median survival rate could be extended possibly surpassing Prostvac's median rate. In any case, we do not know which treatment is better based on the data currently available.
They keep reposting this same sh1t.
They are in phase 2 (Non-US) which means retrial for everything for the US market. In addition, the sampling size is too small.
It's a non-issue. Minimum 5 years away (AT LEAST). Could be 10 years.
PROVENGE extended median survival by 4.1 months compared to placebo (25.8 months versus 21.7 months)....For Provenge to catch up with Prostvac in the 4th year, would be very difficult....Regarding when Prostvac will hit the market. It will not have to. Once preliminary phase III results are out, Provenge is going to have problems. It happens, it just looks like Prostvac is going to be a better therapy. I am sure there is another right behind it from another company. It is a boom and bust world we live in. Gold understands this. The FDA delay has left Provenge is a bad situation with the competition.
The stage II trial ended 4 years ago and the company who conducted the trial no longer exists.
"Therion Biologics developed the vaccine and conducted the initial midstage trial, and former CEO Mark Leuchtenberger said he couldn’t be happier.
“It is a big victory for 100 people at Therion who worked so hard on this — people that are now doing other things.”
That’s where the gets bittersweet part comes in.
The old Therion folks are doing other things because the company no longer exists. Therion shut down in 2006 after disappointing clinical trial results from a cancer vaccine that didn’t pass late-stage clinical trials.
Investors pulled the plug. But Prostvac’s Phase 2 trial results were still pending. Much of its technology was developed by both Therion and the National Cancer Institute, to which the Prostvac rights reverted after NCI sued Therion’s investors. Danish company Bavarian Nordic got to claim all the glory instead. Financial details weren’t disclosed, but Bavarian Nordic licensed the drug not too long ago from the National Cancer Institute.
Bavarian Nordic took the initial study results and called patients from the trial to see who had survived over the past four years. That data follow-up led to the good news announced earlier this month.
Leuchtenberger, now CEO of Targanta Therapeutics Inc. (Nasdaq: TARG) — which is in Therion’s old offices, no less) — said that the Prostvac trial was held from Spring 2004 to the end 2005."
Very detailed post. Lots of information as if you study and research your stock in great detail. No doubt you invest in options. Let me know via a connect link. Don't post your email address.
The NCI is in on it, and in clinical trials to date PROSTVAC™ has been investigated in 464 patients. What was the sample size of the Provenge study? Phase III, hell they already have about the same numbers.